Literature DB >> 14761877

Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.

Yasuhisa Fujii1, Satoru Kawakami, Yohei Okada, Yukio Kageyama, Kazunori Kihara.   

Abstract

Activins are multifunctional growth and differentiation factors and stimulate FSH-beta gene expression and FSH secretion by the pituitary gonadotropes. Follistatins bind activin, resulting in the neutralization of activin bioactivity. The activin/follistatin system is present in the prostate tissue. Prostate-specific antigen (PSA) plays an important role in male reproductive physiology as well as being very important as a tumor marker for prostate cancer. Thus the regulation of PSA has important clinical implications. Previous studies showed that PSA is primarily regulated by androgens. In the present study, we evaluated the direct effects of activin A on the proliferation and PSA production of prostate cancer LNCaP cells, which express functional activin receptors and androgen receptor and PSA. LNCaP cells were treated with activin A and 5alpha-dihydrotestosterone (DHT) with or without their antagonists (follistatin or the nonsteroidal anti-androgen bicalutamide). Activin A decreased cell growth of LNCaP cells in a dose-dependent manner, whereas DHT increased it in a biphasic manner. In contrast to their opposing actions on cell growth, both activin A and DHT upregulated PSA gene expression and increased PSA secretion by LNCaP cells. The effects of activin A and DHT to increase PSA production were synergistic or additive. Follistatin or bicalutamide was without effect on cell growth or PSA production. The effects of activin A on LNCaP cells were blocked by follistatin, not by bicalutamide, whereas effects of DHT were prevented by bicalutamide, not by follistatin. Activin A upregulates PSA production, and the effect is through an androgen receptor-independent pathway. The activin/follistatin system can be a physiological modulator of PSA gene transcription and secretion in the prostate tissue, and activins may cooperate with androgen to upregulate PSA in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14761877     DOI: 10.1152/ajpendo.00443.2003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  10 in total

1.  Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells.

Authors:  Mitchell G Lawrence; Naira V Margaryan; Daniela Loessner; Angus Collins; Kris M Kerr; Megan Turner; Elisabeth A Seftor; Carson R Stephens; John Lai; Lynne-Marie Postovit; Judith A Clements; Mary J C Hendrix
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

Review 2.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

3.  Serum follistatin in patients with prostate cancer metastatic to the bone.

Authors:  Francesca Maria Tumminello; Giuseppe Badalamenti; Fabio Fulfaro; Lorena Incorvaia; Marilena Crescimanno; Carla Flandina; Maria Vittoria Sepporta; Gaetano Leto
Journal:  Clin Exp Metastasis       Date:  2010-07-11       Impact factor: 5.150

4.  Activin A induces apoptosis of mouse myeloma cells via the mitochondrial pathway.

Authors:  Yuanyi Zhang; Yan Qi; Yang Zhao; Hongyan Sun; Jingyan Ge; Zhonghui Liu
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

5.  Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration.

Authors:  BaoHan T Vo; Shafiq A Khan
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

6.  Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

Authors:  Gaetano Leto; Lorena Incorvaia; Giuseppe Badalamenti; Francesca M Tumminello; Nicola Gebbia; Carla Flandina; Marilena Crescimanno; Giovambattista Rini
Journal:  Clin Exp Metastasis       Date:  2006-07-14       Impact factor: 5.150

7.  Basic helix loop helix (bHLH) transcription factor 3 (TCF3, E2A) is regulated by androgens in prostate cancer cells.

Authors:  Divya Patel; Swathi Chinaranagari; Jaideep Chaudhary
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

Review 8.  miRNA and TMPRSS2-ERG do not mind their own business in prostate cancer cells.

Authors:  Sundas Fayyaz; Ammad Ahmad Farooqi
Journal:  Immunogenetics       Date:  2013-04-05       Impact factor: 2.846

9.  Inferring drug-disease associations from integration of chemical, genomic and phenotype data using network propagation.

Authors:  Yu-Fen Huang; Hsiang-Yuan Yeh; Von-Wun Soo
Journal:  BMC Med Genomics       Date:  2013-11-11       Impact factor: 3.063

10.  Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235).

Authors:  R Trauger; E Corey; D Bell; S White; A Garsd; D Stickney; C Reading; J Frincke
Journal:  Br J Cancer       Date:  2009-04-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.